AMNEAL PHARMACEUTICALS, INC. (AMRX) Business Profile

What it does

Amneal Pharmaceuticals develops, manufactures, markets and distributes medicines. Its business spans generic drugs, biosimilars, branded medicines and pharmaceutical distribution. It operates principally in the United States, India and Ireland, and is headquartered in Bridgewater Township. Chirag Patel and Chintu Patel are co-chief executive officers.

The Affordable Medicines business sells generics, injectable medicines and biosimilars. Generics contain the same active ingredient as their branded counterparts and are generally sold at lower prices. Biosimilars are versions of biological medicines, which are made using biological processes. Amneal’s products reach pharmacies, hospitals and other institutions through wholesalers, distributors and direct sales.

The Specialty business develops and sells branded medicines, primarily for central nervous system and endocrine disorders. Its products include CREXONT and RYTARY for Parkinson’s disease, UNITHROID for hypothyroidism, and Brekiya, an injection for acute treatment of migraine and cluster headache in adults. Amneal promotes these medicines to physicians and other healthcare providers.

AvKARE distributes pharmaceuticals and other products to U.S. government, retail and institutional customers. It also repackages medicines and vitamins. Its government business focuses on the Department of Defense and the Department of Veterans Affairs.

How it makes money

Amneal earns revenue from selling medicines it manufactures or sources, selling branded drugs, and distributing and repackaging products through AvKARE. In 2025, Affordable Medicines generated $1.7 billion in revenue. Total net revenue increased 8.0% from the prior year; in the third quarter of 2026, revenue was $863 million, up 10%.

Affordable Medicines includes over 280 product families in the United States, ranging from tablets and liquids to injectables, inhaled medicines, patches and biosimilars. Generic products generally sell below their branded equivalents. Amneal focuses on products with complex formulations, manufacturing requirements or legal and regulatory barriers. Some first-to-file generics can receive a 180-day exclusivity period, subject to conditions. Revenue and margins can be higher around launch or while competition is limited; additional entrants generally pressure volume and pricing.

Specialty revenue comes from branded prescriptions, including CREXONT, RYTARY, UNITHROID and Brekiya. Amneal’s sales teams promote these products to physicians, while the medicines are sold through wholesalers and other channels. The company also licenses products: for example, partners have rights to seek approval and commercialize IPX203, marketed as CREXONT in the United States, in specified overseas territories. Amneal is responsible for manufacturing and supplying those partners after approval.

AvKARE earns revenue by selling and distributing pharmaceuticals and medical products, including to government agencies. It also repackages pharmaceuticals and vitamins. Sales of Amneal products through AvKARE are reported in Affordable Medicines. Sales continue as customers order products, but Amneal does not have long-term agreements with major customers that guarantee future business.

Customers and how it sells

Amneal markets its Affordable Medicines and Specialty products in the United States and Puerto Rico through major wholesalers and distributors, retail and mail-order pharmacies, and directly to hospitals and institutions. It markets most Affordable Medicines products to group purchasing organizations, which negotiate purchases for members, and sells them through wholesalers or directly to large chain retailers and mail-order customers.

Injectables and biosimilars have a dedicated sales force and are generally marketed to purchasing organizations and specialty distributors. Some are sold directly to large hospitals and institutions. Specialty representatives promote branded medicines to physicians, including neurologists, movement disorder specialists, endocrinologists and primary care physicians.

AvKARE serves government agencies, retail and institutional customers throughout the United States. Its institutional distribution customers include organizations providing care to low-income and uninsured patients. The company has approximately 1,300 customers, including over 1,100 within AvKARE.

The four largest customers—Cencora, McKesson, Cardinal Health and CVS Health—accounted for approximately 71% of consolidated net revenue in 2025. Amneal operates principally in the United States, India and Ireland. Its manufacturing network and co-located research centers span those countries, and Affordable Medicines also records revenue from international markets.

Suppliers and costs

Amneal buys raw materials, including active pharmaceutical ingredients, from chemical manufacturers and distributors, and makes some active ingredients at its facilities in India. Some materials are available from only one supplier. For a majority of its products, Amneal has listed only one active-ingredient supplier in applications submitted to the FDA, even where other suppliers may exist. It generally would need as long as 24 to 30 months to find and qualify a replacement sole-source supplier.

The company manufactures most Affordable Medicines products internally and relies on outside manufacturers for part of the portfolio. In 2025, products made at U.S. facilities contributed 46% of Affordable Medicines product net revenue, those made in India contributed 24%, and third-party manufacturers supplied products representing approximately 30% of segment net revenue. Specialty products use both internal and outside manufacturing.

Costs include materials, manufacturing, freight, research and development, sales and marketing, and product launches. Cost of goods sold increased 7.4% in 2025, primarily because of higher sales volume, impairment charges and increased plant and freight costs, partly offset by manufacturing efficiencies. Research spending includes product development, testing, upfront payments and milestones.

Competitive position

Amneal competes with Teva, Viatris, Sandoz, Pfizer, Hikma and other manufacturers in generic medicines and biosimilars. Its specialty-drug competitors include Supernus, Jazz Pharmaceuticals, AbbVie and Alkermes. In distribution and repackaging, AvKARE competes with wholesalers including Cardinal Health, Cencora and McKesson, as well as Golden State Medical Supply.

Competition in generics depends on price, product breadth, quality, reliable supply and the ability to develop and obtain approval for products quickly. Additional generic entrants can reduce prices and volumes. Consolidated wholesalers, retailers and purchasing groups also have buying power. In branded medicines, generic entry after exclusivity expires can cause sales to decline rapidly.

Amneal develops products with complex formulations and manufacturing or regulatory challenges, and selectively makes its own active ingredients. Eligible first-to-file generics can receive a 180-day exclusivity period. The company says its acquisition of Kashiva added biosimilar development and manufacturing capabilities to its commercial business.

Our reading: Complex development and manufacturing capabilities provide some protection against competitors, but their strength varies by product and regulatory barriers do not prevent later entry. Our reading: First-to-file exclusivity can support a temporary advantage rather than a permanent moat, because competing launches can follow its expiry. Our reading: Internal manufacturing and distribution capabilities support supply and customer access, but buyer concentration and competing wholesalers limit their protective value.

Growth opportunities

New products are central to Amneal’s growth plans. As of December 31, 2025, Affordable Medicines had 61 products with pending generic-drug applications and another 43 products in development. The company has prioritized injectables, including long-acting products, drug-device combinations and large-volume bags, as well as inhaled medicines and biosimilars.

Amneal received FDA approval for its lanreotide injectable in September and launched it that month. The company says it closed the Kashiva acquisition in August, adding biosimilar development and manufacturing capabilities. Amneal expects the combined operation to develop and manufacture biosimilars alongside its existing commercial activities. It also plans further biosimilar capacity in New Jersey and India.

In Specialty, the company is developing its branded portfolio alongside products already on the market. CREXONT was added to three large national formularies in 2025, expanding insurance coverage. Amneal is pursuing a second phase four study to evaluate CREXONT’s effect on Parkinson’s disease progression. The company estimates that 700,000 patients in the United States use carbidopa-levodopa therapy.

Amneal is also constructing dedicated drug-substance and drug-product facilities in India for its collaboration with Pfizer on weight-loss medicines. The company says construction remains on track for 2028. Under the collaboration, commercial supply is conditional on regulatory approval, and Amneal has commercialization rights for certain products in selected emerging markets.

Structural risks

• Product development and launches: Developing and commercializing medicines is costly and can be delayed by regulatory reviews, clinical testing, patent litigation or difficulties scaling manufacturing. Approved products also need acceptance by prescribers, patients and payers.
• Price and exclusivity: Competitors and consolidated buyers can pressure generic prices. Branded sales can decline rapidly after exclusivity ends; an authorized generic version of RYTARY launched in 2025, and Amneal anticipates further generic versions.
• Customer concentration: Four customers represented approximately 71% of consolidated net revenue in 2025. Amneal has no long-term agreements with major customers guaranteeing future business, and reduced orders could materially affect results.
• Supply and operations: Some raw materials have a single supplier, and qualifying a replacement can take as long as 24 to 30 months. Amneal also operates international facilities exposed to regulatory, economic and political uncertainty.
• Debt and regulation: Amneal has substantial indebtedness, including some variable-rate debt, which can limit financing and require cash-flow payments. Its products and facilities are subject to extensive regulation, and noncompliance can lead to recalls, production suspensions or other enforcement.

Leadership

The Amneal Group owns nearly a majority of Amneal’s outstanding Class A common stock.

Bottom line

Our reading

Our reading: Amneal combines a large generic-medicines business with branded drugs and distribution, and relies on new launches to replenish products exposed to competition (item1, item7). Our reading: Complex manufacturing and the expanded biosimilars operation can support that pipeline, while concentrated customers, sole-source inputs and debt remain material exposures (item1, item1a, call_prepared).